Amrn.
Brokerage ponen a corto plazo Precio objetivo de Amrn en 6,50$
http://www.tricitystate.com/brokerage-firm-price-target-on-amarin-corporation-plc/35882/
Amrn
AMRN.
anunció hoy la presentación de los hallazgos de un estudio in vitro mostrando el pretratamiento con ácido eicosapentaenoico (EPA), un ácido graso omega-3, q reduce la oxidación de las LDL densa pequeño (sdLDL) y resultó en la función endotelial mejorada en comparación con otra triglicérido (TG)-reducción de agentes, incluyendo fenofibrates, niacina y gemfibrozil.
New In Vitro Study Presented at the American College of Cardiology Meeting Suggests Omega-3 Fatty Acid EPA Pre-Treatment Reduces Oxidative Damage and May Provide Atheroprotective Benefit Versus Other Triglyceride Lowering Agents
http://finance.yahoo.com/news/vitro-study-presented-american-college-203000684.html?soc_src=mediacontentsharebuttons&soc_trk=ma
Amrn
Artículo thld
Efficacy and safety of the hypoxia-activated prodrug TH-302 in combination with gemcitabine and nab-paclitaxel in human tumor xenograft models of pancreatic cancer.
Eficacia y seguridad de la hipoxia activado Profármaco TH-302 en combinación con gemcitabina y nab-paclitaxel en modelos de xenoinjerto tumorales humanas de cáncer de páncreas.
http://www.ncbi.nlm.nih.gov/pubmed/25679067
Thld
Thld
EDISON EQUITY RESEARCH: THRESHOLD PHARMACEUTICALS - ON THE THRESHOLD OF A BLOCKBUSTER OPPORTUNITY
Phase III data for evofosfamide (TH-302) in soft tissue sarcoma (STS) and pancreatic cancer are expected by early 2016. These two indications alone could lead to blockbuster sales with partner Merck KGaA. Our estimates suggest the current market cap is more than underpinned by the risk-adjusted potential in STS together with net cash. We value Threshold at $949m based on evofosfamide in STS and pancreatic cancer and in a number of further opportunities in other solid tumours and blood cancers.
Threshold Pharmaceuticals is a US oncology company focused on tumour hypoxia, a low-oxygen condition found in most solid tumours and some blood cancers. Evofosfamide is in Phase III for STS and pancreatic cancer and earlier trials in multiple other cancers, and is partnered with Merck KGaA.
http://ih.advfn.com/p.php?adw=1126416&article=65822260&pid=nmona&xref=newsalerttweet
Thld
Calendario de la FDA
http://www.biopharmcatalyst.com/2015/03/pipeline-updates-for-aeri-aldx-aliof-amrn-aqxp-athx-blrx-bota-cvm-drrx-dvax-gern-mdco-mgnx-pcrx-ptla-rcpt-rigl-rvnc-thld-tnxp-tthi-xlrn/
Amrn, Thld ...
Esta fue una favorita del TITO , ya le saque algo en su día y pinta bien.
Voy haber si me devuelve algo de Amrn.
Tus NVAX se me escaparon por no tener CASH,
Enhorabuena ,tb po el SUBIDON
Snss
THLD anuncia presentación y Webcast en la Conferencia de salud 2015.
http://finance.yahoo.com/news/threshold-pharmaceuticals-announces-presentation-webcast-120000877.html
THLD